Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
1p/19q Codeletion
16%
ATRX mutation
33%
Chemoradiotherapy
33%
Contrast Enhancement
50%
Diffuse Glioma
100%
Early Tumor Progression
16%
EGFR mutation
16%
Glioma
16%
Histopathological Features
100%
IDH mutation
33%
IDH-wildtype
16%
IDH1-R132H
16%
Imaging Findings
16%
Immunohistochemistry
16%
Isocitrate Dehydrogenase 1 (IDH1)
16%
Low Dose Rate
16%
Mixed Oligoastrocytoma
66%
Molecular Characteristics
100%
Next-generation Sequencing
16%
Oligodendroglioma
66%
Pathologic
16%
Pseudoprogression
100%
Re-resection
33%
Residual Tumor
16%
TP53 mutation
33%
Treatment Effect
33%
Tumor
66%
Tumor Progression
16%
WHO Grade II
16%
WHO Grade III
16%
Medicine and Dentistry
Chemoradiotherapy
50%
Epidermal Growth Factor Receptor
25%
Ganglioglioma
100%
Immunohistochemistry
25%
Neoplasm
25%
Next Generation Sequencing
25%
Oligoastrocytoma
100%
Oligodendroglioma
100%
Treatment Effect
50%
Tumor
100%
Tumor Progression
50%
Biochemistry, Genetics and Molecular Biology
Alpha Thalassemia/Mental Retardation X-Linked
50%
Contrast Enhancement
75%
Epidermal Growth Factor Receptor
25%
IDH1
100%
Next Generation Sequencing
25%
Tumor Progression
50%
Wild Type
50%
Pharmacology, Toxicology and Pharmaceutical Science
Astrocytoma
100%
Chemoradiation Therapy
50%
Epidermal Growth Factor Receptor
25%
Neoplasm
25%
Oligodendroglioma
100%
Tumor Growth
50%
Neuroscience
Epidermal Growth Factor Receptor
25%
Immunohistochemistry
25%
Oligodendroglioma
100%
TP53
50%
Immunology and Microbiology
Next Generation Sequencing
16%
Pseudoprogression
100%
Wild Type
33%